These innovative molecules represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose https://janegklf395546.blogrenanda.com/45860862/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide